Editorial: KRAS and TP53 mutations in colorectal carcinoma

Saudi Journal of Gastroenterology

Volumn 15, Issue 4, 2009, Pages 217-219

  Al Kuraya, Khawla S ^a,b  

^a Research Center   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; CETUXIMAB; CYSTEINE; CYTOKINE RECEPTOR; DNA; GLYCINE; GROWTH FACTOR; GUANINE; HORMONE; MISMATCH REPAIR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PROTEIN KINASE B; PROTEIN P53; THREONINE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

AMINO ACID SUBSTITUTION; CANCER GROWTH; CELL FUNCTION; CHROMOSOMAL INSTABILITY; CODON; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOKINE PRODUCTION; EDITORIAL; ETHNIC DIFFERENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE INSERTION; GENE LOSS; GENE MUTATION; GENETIC DIFFERENCE; HUMAN; LOSS OF FUNCTION MUTATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE K RAS; POINT MUTATION; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; COLORECTAL TUMOR; GENETICS; MUTATION;

COLORECTAL NEOPLASMS; GENES, P53; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 70349823495     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.56087     Document Type: Editorial

References (29)

1. Khamly K, Jefford M, Michael M, Zalcberg J. Beyond 5-fluorouracil: New horizons in systemic therapy for advanced colorectal cancer. Expert Opin Investig Drugs 2005;14:607-628
2. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508
3. Jass J.R. Colorectal cancer: A multipathway disease. Crit Rev Oncogenesis 2006;12:273-287
4. Lengauer C, Kinzler K W, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-627
5. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58: 5248-5257
6. Kinzler K W, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170
7. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532
8. Sameer AS, Pandith AS, Syeed N, Chowdhri NA, Alam KA, Siddiqi MA. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol 2009;15:244-252
9. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-614
10. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008;27:3539-3545 (Pubitemid 351793794)
11. Anwar S, Frayling IM, Scott NA, Carlson GL. Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 2004;91:1275-1291
12. Mir MM, Dar NA, Gochhait S, Zargar SA, Ahangar AG, Bamezai RN. p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): A high-incidence area. Int J Cancer 2005;116:62-68
13. Malumbres M, Barbacid M. RAS oncogenes: The first 30 years. Nat Rev 2003;3:459-465
14. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995
15. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-1857
16. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-1074
17. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-4689
18. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767
19. Brink M, de Goeij A F, Weijenberg M P, Roemen GM, Lentjes MH, Pachen MM, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003;24:703-710
20. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-297
21. Capon DJ, Seeburg PH, McGrath J P, Hayflick JS, Edman U, Levinson AD, et al. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 1983;304:507-513
22. Beranek M, Bures J, Palicka V, Jandik P, Langr F, Nejedla E. A relationship between K-ras gene mutations and some clinical and histologic variables in patients with primary colorectal carcinoma. Clin Chem Lab Med 1999;37:723-727
23. Urosevic N, Krtolica K, Skaro-Milic A, Knezevic-Usaj S, Dujic A. Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 1993;54:249-254
24. Martinez-Garza SG, Nunez-Salazar A, Calderon-Garciduenas AL, Bosques-Padilla FJ, Niderhauser-Garcia A, Barrera-Saldana HA. Frequency and clinicopathology associations of K-ras mutations in colorectal cancer in a northeast Mexican population. Dig Dis 1999;17:225-229
25. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122:2255-2259
26. Conzelmann M, Linnemann U, Berger MR. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients. Int J Oncol 2004;24: 1537-1544
27. Stewart BW K P. World Cancer Report. Lyon: IARC Press; 2003.
28. Hartmann A, Blaszyk H, Saitoh S, Tsushima K, Tamura Y, Cunningham JM, et al. High frequency of p53 gene mutations in primary breast cancers in Japanese women: A low-incidence population. Br J Cancer 1996;73:896-901.
29. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007;60:768-772